News | Breast Imaging | October 31, 2022

Newest grant brings total to $2 million for studies that could result in new therapeutic approaches 

Newest grant brings total to $2 million for studies that could result in new therapeutic approaches

Getty Images


October 31, 2022 —  The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer

The latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment. 

“We are delighted and grateful to receive this grant from the Foundation, which recognizes the expertise and the commitment of both the Icahn School of Medicine at Mount Sinai and the Dubin Breast Center with regard to developing novel therapeutics for a diverse group of patients with high-risk breast cancers,” said Dr. Port, Chief of Breast Surgery for the Mount Sinai Health System and Director of the Dubin Breast Center of The Tisch Cancer Institute at Icahn Mount Sinai. 

“This funding also recognizes our innovative efforts to advance the field’s understanding of this disease, such as our Breast Cancer Biorepository, an impressive bank of patient breast tumor tissue and blood samples that is enabling us to make research breakthroughs,” Dr. Port said. “This grant, combined with our extensive resources and knowledge, provides us with invaluable support to identify treatments that could have significant benefits for our patients, and for millions of women worldwide.” 

Typically diagnosed among women under the age of 50, triple-negative breast cancer is a subtype of breast cancer that has an estimated prevalence between 10-15 percent of all breast cancer cases. It can be particularly challenging to treat, in part because it is aggressive and thus has a higher risk of relapse, but also because the options available for treatment are limited. Although immunotherapy is increasingly used in the treatment of triple-negative breast cancer, not all patients respond to or benefit from this approach. Thus, more research is required among patients to understand how their immune system interacts with breast cancer cells and how it works to control cancer growth and spread both within the tumor itself and in other parts of the body. 

“Our BCRF-funded studies will explore those interactions between breast cancer cells and the immune system, specifically focusing on cancer stem cells,” said Dr. Irie, Associate Professor of Medicine (Hematology and Medical Oncology), and Oncological Sciences, at the Dubin Breast Center. “Breast cancer stem cells are less likely to be eliminated by chemotherapy or immunotherapy, and our goal is to develop strategies that simultaneously kill triple-negative breast cancer stem cells and enhance anti-tumor immune responses. We have identified several promising candidate drugs that induce these effects in preclinical models of triple-negative breast cancer, and we are working to clinically translate them so that we can achieve improved results for our patients.” 

Founded in 1993 by Evelyn H. Lauder, BCRF is the largest private funder of breast cancer research in the world. By investing in the best minds in science—those investigating prevention, diagnosis, treatment, survivorship, and metastasis—and fostering cross-disciplinary collaboration, BCRF is accelerating the field to find the answers that are urgently needed to achieve the end of breast cancer. 

For more information: https://www.bcrf.org/ 

Related Content: 

Georgia Cancer Center Researcher Receives $1.7M Grant to Study Aggressive Form of Breast Cancer  

The Role of PET Imaging in Preclinical Oncology 

Black Women Are Receiving Inferior Breast Screening 


Related Content

News | Mammography

November 29, 2022 — One in five women is likely to forgo additional testing after an abnormal finding on a screening ...

Time November 29, 2022
arrow
News | Mammography

November 28, 2022 — The Radiological Society of North America (RSNA) has announced the launch of the RSNA Screening ...

Time November 28, 2022
arrow
News | Artificial Intelligence

November 28, 2022 — Flywheel, a leading data management platform for biomedical research and collaboration, is creating ...

Time November 28, 2022
arrow
News | Breast Imaging

November 25, 2022 — Hologic, Inc. will exhibit its extensive portfolio of breast and skeletal health products at the ...

Time November 25, 2022
arrow
News | Artificial Intelligence

November 25, 2022 — Delphinus Medical Technologies has announced the installation of its SoftVue 3D Whole Breast ...

Time November 25, 2022
arrow
News | Ultrasound Women's Health

November 22, 2022 — Sirona Medical, the leader in cloud-native radiology workflow software, today announced a ...

Time November 22, 2022
arrow
News | Ultrasound Women's Health

November 22, 2022 — Delphinus Medical Technologies today announced that it will host demonstrations of the commercially ...

Time November 22, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
Feature | Breast Imaging | By Andrew Smith and Paola Wisner

Patients are the motivational driver for innovation in breast imaging companies. Their needs and experiences help ...

Time November 04, 2022
arrow
News | Mammography

November 3, 2022 — Hologic, Inc., a global leader in women’s health, announced that its 3Dimensions mammography system ...

Time November 03, 2022
arrow
Subscribe Now